Log in
Enquire now
Atrovent

Atrovent

ipratropium bromide

OverviewStructured DataIssuesContributors

Contents

boehringer-ingelheim.com/products/atrovent
Is a
Product
Product

Product attributes

Industry
Medicine
Medicine
Product Parent Company
Boehringer Ingelheim
Boehringer Ingelheim

Ipratropium bromide, sold under the trade name Atrovent among others, is a type of anticholinergic, a medication which opens up the medium and large airways in the lungs. It is used to treat the symptoms of chronic obstructive pulmonary disease and asthma. It is used by inhaler or nebulizer. Onset of action is typically within 15 to 30 minutes and lasts for three to five hours.

Common side effects include dry mouth, cough, and inflammation of the airways. Potentially serious side effects include urinary retention, worsening spasms of the airways, and a severe allergic reaction. It appears to be safe in pregnancy and breastfeeding. Ipratropium is a short-acting muscarinic antagonist, which works by causing smooth muscles to relax.

Ipratropium bromide was patented in 1966, and approved for medical use in 1974. It is on the World Health Organization's List of Essential Medicines, the most important medicines needed in a health system. Ipratropium is available as a generic medication. In 2017, it was the 216th most commonly prescribed medication in the United States, with more than two million prescriptions.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Atrovent

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.